中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 5
May  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(5): 993-998

Perspectives in the development of new drugs against hepatitis B virus

DOI: 10.3969/j.issn.1001-5256.2021.05.001
  • 1.

    Department of Cancer Research, College of Life Sciences, Nankai University, Tianjin 300071, China

  • 2.

    Tianjin Cancer Institute, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

  • Received Date: 2021-02-25
  • Accepted Date: 2021-03-24
  • Published Date: 2021-05-20
    Abstract
  • Hepatitis B is a chronic infectious disease caused by hepatitis B virus (HBV) infection, with liver inflammatory lesions as the main clinical manifestation, and continuous replication of HBV can lead to abnormal liver function, liver cirrhosis, and even liver cancer. At present, a variety of anti-HBV drugs have been applied in clinical practice, but no satisfactory therapeutic effect has been achieved. Therefore, it is urgent to develop new anti-HBV drugs and constantly update the concept of anti-HBV treatment. This article reviews the research advances in anti-HBV drugs and drugs that block the interaction between the host and the virus, proposes the new idea of the combination of anti-HBV drugs and the drugs blocking the interaction between the host and the virus, and looks into the future of the development of new drugs against HBV, so as to improve the cure rate of hepatitis B.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386(10003): 1546-1555. DOI: 10.1016/S0140-6736(15)61412-X.
    [2]
    HOOFNAGLE JH, LAU D. New therapies for chronic hepatitis B[J]. J Viral Hepat, 1997, 4(Suppl 1): 41-50. DOI: 10.1111/j.1365-2893.1997.tb00159.x.
    [3]
    LIANG TJ, BLOCK TM, MCMAHON BJ, et al. Present and future therapies of hepatitis B: From discovery to cure[J]. Hepatology, 2015, 62(6): 1893-1908. DOI: 10.1002/hep.28025.
    [4]
    SUNG JJ, WONG ML, BOWDEN S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy[J]. Gastroenterology, 2005, 128(7): 1890-1897. DOI: 10.1053/j.gastro.2005.03.009.
    [5]
    WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J]. Gastroenterology, 2004, 126(7): 1750-1758. DOI: 10.1053/j.gastro.2004.03.018.
    [6]
    GOVAN L, WU O, XIN Y, et al. Comparative effectiveness of antiviral treatment for hepatitis B: A systematic review and Bayesian network meta-analysis[J]. Eur J Gastroenterol Hepatol, 2015, 27(8): 882-894. DOI: 10.1097/MEG.0000000000000376.
    [7]
    YE X, ZHOU M, HE Y, et al. Efficient inhibition of hepatitis B virus infection by a preS1-binding Peptide[J]. Sci Rep, 2016, 6: 29391. DOI: 10.1038/srep29391.
    [8]
    KANEKO M, WATASHI K, KAMISUKI S, et al. A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide[J]. J Virol, 2015, 89(23): 11945-11953. DOI: 10.1128/JVI.01855-15.
    [9]
    DONG Z, EKINS S, POLLI JE. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)[J]. Mol Pharm, 2013, 10(3): 1008-1019. DOI: 10.1021/mp300453k.
    [10]
    YAN H, LIU Y, SUI J, et al. NTCP opens the door for hepatitis B virus infection[J]. Antiviral Res, 2015, 121: 24-30. DOI: 10.1016/j.antiviral.2015.06.002.
    [11]
    VOLZ T, ALLWEISS L, BEN MBAREK M, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus[J]. J Hepatol, 2013, 58(5): 861-867. DOI: 10.1016/j.jhep.2012.12.008.
    [12]
    BLANK A, MARKERT C, HOHMANN N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B[J]. J Hepatol, 2016, 65(3): 483-489. DOI: 10.1016/j.jhep.2016.04.013.
    [13]
    CARTHEW RW, SONTHEIMER EJ. Origins and Mechanisms of miRNAs and siRNAs[J]. Cell, 2009, 136(4): 642-655. DOI: 10.1016/j.cell.2009.01.035.
    [14]
    YUEN MF, SCHIEFKE I, YOON JH, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection[J]. Hepatology, 2020, 72(1): 19-31. DOI: 10.1002/hep.31008.
    [15]
    GISH RG, YUEN MF, CHAN HL, et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent[J]. Antiviral Res, 2015, 121: 97-108. DOI: 10.1016/j.antiviral.2015.06.019.
    [16]
    BUTI M, ESTEBAN R. Drugs in development for hepatitis B[J]. Drugs, 2005, 65(11): 1451-1460. DOI: 10.2165/00003495-200565110-00001.
    [17]
    LIU J, ZHANG S, WANG Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: A population-based, cross-sectional study[J]. Lancet Infect Dis, 2016, 16(1): 80-86. DOI: 10.1016/S1473-3099(15)00218-2.
    [18]
    FUNG J, WONG T, CHOK K, et al. Oral nucleos(t)ide analogs alone after liver transplantation in chronic hepatitis B with preexisting rt204 mutation[J]. Transplantation, 2017, 101(10): 2391-2398. DOI: 10.1097/TP.0000000000001883.
    [19]
    ZHOU J, LIU YY, LIAN JS, et al. Efficacy and safety of tenofovir disoproxil treatment for chronic hepatitis B patients with genotypic resistance to other nucleoside analogues: A prospective study[J]. Chin Med J (Engl), 2017, 130(8): 914-919. DOI: 10.4103/0366-6999.204107.
    [20]
    BERKE JM, DEHERTOGH P, VERGAUWEN K, et al. Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus[J]. Antimicrob Agents Chemother, 2017, 61(8). DOI: 10.1128/AAC.00560-17.
    [21]
    KLUMPP K, LAM AM, LUKACS C, et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein[J]. Proc Natl Acad Sci U S A, 2015, 112(49): 15196-15201. DOI: 10.1073/pnas.1513803112.
    [22]
    DEWITT MA, MAGIS W, BRAY NL, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells[J]. Sci Transl Med, 2016, 8(360): 360ra134. DOI: 10.1126/scitranslmed.aaf9336.
    [23]
    RAMANAN V, SHLOMAI A, COX DB, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus[J]. Sci Rep, 2015, 5: 10833. DOI: 10.1038/srep10833.
    [24]
    WANG J, CHEN R, ZHANG R, et al. The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication[J]. Theranostics, 2017, 7(12): 3090-3105. DOI: 10.7150/thno.18114.
    [25]
    LOK AS, PAN CQ, HAN SH, et al. Randomized phase Ⅱ study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B[J]. J Hepatol, 2016, 65(3): 509-516. DOI: 10.1016/j.jhep.2016.05.016.
    [26]
    MENNE S, TUMAS DB, LIU KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B[J]. J Hepatol, 2015, 62(6): 1237-1245. DOI: 10.1016/j.jhep.2014.12.026.
    [27]
    LANFORD RE, GUERRA B, CHAVEZ D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J]. Gastroenterology, 2013, 144(7): 1508-1517, 1517. e1-10. DOI: 10.1053/j.gastro.2013.02.003.
    [28]
    GANE EJ, LIM YS, GORDON SC, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J]. J Hepatol, 2015, 63(2): 320-328. DOI: 10.1016/j.jhep.2015.02.037.
    [29]
    JANSSEN H, BRUNETTO MR, KIM YJ, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B[J]. J Hepatol, 2018, 68(3): 431-440. DOI: 10.1016/j.jhep.2017.10.027.
    [30]
    SCHINAZI RF, EHTESHAMI M, BASSIT L, et al. Towards HBV curative therapies[J]. Liver Int, 2018, 38(Suppl 1): 102-114. DOI: 10.1111/liv.13656.
    [31]
    SHIN YW, CHO DH, SONG GW, et al. A New ELISA to overcome the pitfalls in quantification of recombinant human monoclonal Anti-HBs, GC1102, by commercial immunoassays[J]. Biol Proced Online, 2018, 20: 18. DOI: 10.1186/s12575-018-0083-8.
    [32]
    CHEN J, WANG XM, WU XJ, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B[J]. Inflamm Res, 2011, 60(1): 47-53. DOI: 10.1007/s00011-010-0233-1.
    [33]
    GANE E, VERDON DJ, BROOKS AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study[J]. J Hepatol, 2019, 71(5): 900-907. DOI: 10.1016/j.jhep.2019.06.028.
    [34]
    BOCK CT, SCHRANZ P, SCHRZÖDER CH, et al. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell[J]. Virus Genes, 1994, 8(3): 215-229. DOI: 10.1007/BF01703079.
    [35]
    BOCK CT, SCHWINN S, LOCARNINI S, et al. Structural organization of the hepatitis B virus minichromosome[J]. J Mol Biol, 2001, 307(1): 183-196. DOI: 10.1006/jmbi.2000.4481.
    [36]
    DAWSON MA. The cancer epigenome: Concepts, challenges, and therapeutic opportunities[J]. Science, 2017, 355(6330): 1147-1152. DOI: 10.1126/science.aam7304.
    [37]
    GHOSH SK, PERRINE SP, WILLIAMS RM, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents[J]. Blood, 2012, 119(4): 1008-1017. DOI: 10.1182/blood-2011-06-362434.
    [38]
    BARLOW DP. Methylation and imprinting: From host defense to gene regulation?[J]. Science, 1993, 260(5106): 309-310. DOI: 10.1126/science.8469984.
    [39]
    VIVEKANANDAN P, DANIEL HD, KANNANGAI R, et al. Hepatitis B virus replication induces methylation of both host and viral DNA[J]. J Virol, 2010, 84(9): 4321-4329. DOI: 10.1128/JVI.02280-09.
    [40]
    SHIM YH, YOON GS, CHOI HJ, et al. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis[J]. Cancer Lett, 2003, 190(2): 213-219. DOI: 10.1016/s0304-3835(02)00613-4.
    [41]
    ZHENG DL, ZHANG L, CHENG N, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A[J]. J Hepatol, 2009, 50(2): 377-387. DOI: 10.1016/j.jhep.2008.10.019.
    [42]
    TROPBERGER P, MERCIER A, ROBINSON M, et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation[J]. Proc Natl Acad Sci U S A, 2015, 112(42): e5715-e5724. DOI: 10.1073/pnas.1518090112.
    [43]
    ZHANG W, CHEN J, WU M, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation[J]. Hepatology, 2017, 66(2): 398-415. DOI: 10.1002/hep.29133.
    • Relative Articles
    • Supplements(1)
  • 抗HBV新药展望 附录1.pdf
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1000) PDF downloads(216) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return